Document Detail

Time course of serum testosterone and luteinizing hormone levels after cessation of long-term luteinizing hormone-releasing hormone agonist treatment in patients with prostate cancer.
MedLine Citation:
PMID:  16329145     Owner:  NLM     Status:  MEDLINE    
INTRODUCTION: In order to elucidate the influence of hormone-releasing hormone (LH-RH) agonist therapy cessation on pituitary/testicular function and its clinical implications, we investigated prospectively hormonal (luteinizing hormone: LH; testosterone: T) responses in patients with prostate cancer who received long-term LH-RH 10 agonist therapy. PATIENTS AND METHODS: A consecutive 32 patients who had received LH-RH agonist therapy over 24 months were enrolled. As a baseline, T and LH were measured at the time of LH-RH agonist therapy cessation, monthly for 3 months, and subsequently, every 3 months. RESULTS: The median duration of LH-RH agonist therapy was 30 months (24-87 months) with median follow-up duration of 24 months following cessation. All patients had castrated T levels and suppressed LH levels at baseline. Median duration of castrated T levels following cessation was 6 months. Median time to normalization of T levels was 24 months. LH levels returned to normal within 3 months in all cases. Patients who received androgen deprivation therapy for 30 months or longer required a longer time for recovery of T levels. Patients over 65 years of age showed a statistically significant longer time for recovery of T levels (P=0.0167). CONCLUSIONS: Long-term LH-RH agonist therapy has remarkable effects on serum T level that last for a significant time after cessation, a fact that should be applied to the interpretation of both PSA and serum T levels after cessation of androgen deprivation therapy.
Haruki Kaku; Takashi Saika; Tomoyasu Tsushima; Shin Ebara; Takashi Senoh; Toyoko Yamato; Yasutomo Nasu; Hiromi Kumon
Related Documents :
23419605 - Arthroscopic subacromial decompression and predictors of long-term sick leave benefit a...
20588115 - The diagnosis and treatment of growth hormone deficiency in adults.
19643255 - Percutaneous treatment of lymphatic malformations.
7786425 - Pituitary function after selective adenomectomy for cushing's disease.
23962035 - Two-year results of photodynamic therapy with or without intravitreal ranibizumab for p...
19644275 - Isolated capitate shortening osteotomy for the early stage of kienböck disease with ne...
Publication Detail:
Type:  Clinical Trial; Journal Article    
Journal Detail:
Title:  The Prostate     Volume:  66     ISSN:  0270-4137     ISO Abbreviation:  Prostate     Publication Date:  2006 Mar 
Date Detail:
Created Date:  2006-01-23     Completed Date:  2006-04-13     Revised Date:  2006-11-15    
Medline Journal Info:
Nlm Unique ID:  8101368     Medline TA:  Prostate     Country:  United States    
Other Details:
Languages:  eng     Pagination:  439-44     Citation Subset:  IM    
Copyright Information:
(c) 2005 Wiley-Liss, Inc.
Department of Urology, Okayama University, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Aged, 80 and over
Antineoplastic Agents, Hormonal / pharmacology*
Gonadotropin-Releasing Hormone / agonists*,  physiology
Luteinizing Hormone / blood*
Middle Aged
Pituitary Gland / drug effects,  physiology
Prospective Studies
Prostatic Neoplasms / drug therapy*,  pathology
Testis / drug effects,  physiology
Testosterone / blood*
Reg. No./Substance:
0/Antineoplastic Agents, Hormonal; 33515-09-2/Gonadotropin-Releasing Hormone; 58-22-0/Testosterone; 9002-67-9/Luteinizing Hormone

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Three-dimensional cell seeding and growth in radial-flow perfusion bioreactor for in vitro tissue re...
Next Document:  Loss of Betaig-h3 protein is frequent in primary lung carcinoma and related to tumorigenic phenotype...